A5033873648- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Frailty in Older Adults
- Nutrition and Health in Aging
- Inflammatory Bowel Disease
- Health Systems, Economic Evaluations, Quality of Life
- Diet and metabolism studies
- Adipokines, Inflammation, and Metabolic Diseases
- Microscopic Colitis
- Parkinson's Disease Mechanisms and Treatments
- Neurological Disease Mechanisms and Treatments
- Amyotrophic Lateral Sclerosis Research
- Clinical Nutrition and Gastroenterology
- Drug Transport and Resistance Mechanisms
- Autoimmune Neurological Disorders and Treatments
- Bariatric Surgery and Outcomes
- Gastrointestinal disorders and treatments
- Esophageal and GI Pathology
- Eosinophilic Esophagitis
- Regulation of Appetite and Obesity
- Pancreatitis Pathology and Treatment
- Pain Management and Opioid Use
- Health, Environment, Cognitive Aging
- Biochemical Analysis and Sensing Techniques
- Cerebral Palsy and Movement Disorders
Assistance Publique – Hôpitaux de Paris
2016-2025
Sorbonne Paris Cité
2019-2025
Université Paris Cité
2012-2025
Inserm
2014-2025
Hôpital Fernand-Widal
2019-2025
Hôpital Bichat-Claude-Bernard
2014-2025
Université Claude Bernard Lyon 1
2014-2025
Hôpital Lariboisière
2019-2024
Optimisation Thérapeutique en Neuropsychopharmacologie
2021-2024
Nord University
2023
Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that increases in the cerebrospinal fluid (CSF) and blood individuals with Alzheimer disease (AD). However, it not known whether there are differences GFAP levels across entire AD continuum its performance similar to CSF GFAP.To evaluate plasma throughout continuum, from preclinical dementia, compared GFAP.This observational, cross-sectional study collected data July 29, 2014, January 31, 2020, 3 centers. The...
<h3>Importance</h3> Plasma phosphorylated tau (p-tau) has proven to be an accurate biomarker for Alzheimer disease (AD) pathologic characteristics, offering a less expensive and invasive alternative cerebrospinal fluid (CSF) positron emission tomography biomarkers amyloid-β tau. comorbid characteristics are common associated with more rapid cognitive decline in patients dementia Lewy bodies (DLB); therefore, it is anticipated that plasma p-tau concentrations may have utility assessing...
To assess the validity of Mini Nutritional Assessment-Short Form (MNA-SF) in elderly patients from Toulouse Frailty Platform.
The ε4 allele of apolipoprotein E (APOE) gene and increasing age are two the most important known risk factors for developing Alzheimer disease (AD). diagnosis AD based on clinical symptoms alone is to have poor specificity; recently developed diagnostic criteria biomarkers that reflect underlying neuropathology allow better assessment strength associations with AD. Accordingly, we examined global age-specific association between APOE genotype by using A/T/N classification, relying...
Some reports have suggested that infliximab may induce obstructive symptoms and, although there is no firm evidence, it usually contra-indicated in-patients with Crohn's disease (CD) and strictures.To evaluate the effect of on symptomatic strictures small intestine in CD to identify predictive factors clinical response.This retrospective study included patients treated after conventional treatment had failed. The short-term (week 8) long-term results were classified according predefined...
Direct oral anticoagulants have been evaluated in the general population, but proper evidence for their safe use geriatric population is still missing. We compared bleeding risk of a direct anticoagulant (rivaroxaban) and vitamin K antagonists (VKAs) among French patients with non-valvular atrial fibrillation (AF) aged ≥80 years.We performed sequential observational prospective cohort study, using data from 33 centres. The sample comprised 908 newly initiated on VKAs between September 2011...
Increasing evidence supports the use of plasma biomarkers amyloid, tau, neurodegeneration, and neuroinflammation for diagnosis dementia. However, their performance positive differential dementia with Lewy bodies (DLB) in clinical settings is still uncertain.
The use of cerebrospinal (CSF) biomarkers in the diagnosis Alzheimer's disease (AD) has been gaining interest clinical practice. Although their usefulness demonstrated, potential value older patients remains debated. To assess whether knowledge results CSF AD was associated with same gain diagnostic confidence adults > 80 than younger patients. Prospective multicenter study, including memory clinics physicians who completed a two-part questionnaire for all addressing requirement assessment...
Abstract Background While upadacitinib has demonstrated its efficacy as an induction treatment for Crohn’s disease (CD) in two phase 3 randomized, placebo-controlled trials1, real-world data remain limited. Methods From September 2022 to 2024, all consecutive patients with refractory CD treated once-daily 45 mg 30 French and Belgian GETAID centres were retrospectively included. The primary endpoint was steroid-free clinical remission (SFCR) at week 12, defined a Harvey-Bradshaw Index (HBI)...
Abstract Background Subcutaneous (SC) vedolizumab (VDZ) has demonstrated its efficacy and safety in patients with moderate-to-severe ulcerative colitis (UC) Crohn’s disease (CD). This study aimed to evaluate the effectiveness of SC VDZ dose intensification IBD an incomplete clinical response or loss response. Methods We conducted a retrospective international 25 centers from August 2023 April 2024. All active CD UC, as defined by patient-reported outcomes (PRO2), who had lost required...
Abstract Background Upadacitinib has demonstrated efficacy as an induction treatment for Crohn’s disease (CD)1, and a post hoc analysis of phase 3 randomized, placebo-controlled trials shown its in perianal fistulizing CD (pCD)2. However, real-world data this setting remain limited. Methods From September 2022 to 2024, all consecutive patients with treated once-daily upadacitinib 45 mg 32 French Belgian GETAID centres were retrospectively included. Clinical remission (absence draining pus...
Abstract Alzheimer's disease (AD) is associated with early metabolic dysfunction and adiponectin, which may play a pathophysiological role. Adiponectin implicated in the regulation of energy homeostasis, carbohydrate, lipid metabolism, as well inflammation modulation. The aim this study was to whether plasma adiponectin levels were different between patients AD confirmed by biomarkers neurological control subjects. We performed monocentric, retrospective, cross‐sectional, observational...
Real-world effectiveness and safety of upadacitinib in patients with Crohn's disease (CD) remain unclear. This study aimed to evaluate the a real-world cohort. From September 2022 June 2024, all consecutive refractory luminal CD treated once daily 45 mg 29 French GETAID centres were retrospectively included. The primary outcome was steroid-free clinical remission (SFCR) at week 12, defined as Harvey-Bradshaw Index (HBI) < 4. Clinical response (decrease ≥ 3 points HBI and/or 4), remission,...
To examine whether the Mini Nutritional Assessment-Short Form (MNA-SF) score and its individual items are predictors of mortality in a nursing home population.